NCT04118075View on ClinicalTrials.gov

PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

May 1, 2021

Study Completion Date

May 1, 2021

Conditions
GVHD, Acute
Interventions
DRUG

PT-CY-FK +/-ATG

GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.

Trial Locations (1)

200025

Rui Jin Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT04118075 - PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT | Biotech Hunter | Biotech Hunter